The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized powder, long term |
| Common analytical method | Reverse-phase HPLC | Usually paired with mass spectrometry |
| Typical reported purity | At or above 95 percent by area | Research-grade material |
| Aqueous solubility | High | Solutions used in laboratory assays |
| Moisture sensitivity | Hydrolyzes in solution | Aseptic handling reduces degradation |
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
== Later research == Later research projects conducted by Leeman and her lab were centered around the two peptides, substance P and neurotensin, that she originally isolated, sequenced, and synthesized. Her lab at Boston University has multiple goals regarding these neural peptides, including mapping their distribution within the brain and peripheral nervous system, delineating tracts containing substance P or neurotensin within the central nervous system, determining how substance P and neurotensin are released from neural tissue in vitro and in vivo, and identifying the binding domain of substance P with its receptor.
=== Animal health === One meta-analysis published in 2003 suggested a negative impact of rBST's effects on bovine health. Findings suggested an average increase in milk output ranging from 11–16%, an approximate 24% increase in the risk of clinical mastitis, a 40% reduction in fertility, and 55% increased risk of developing clinical signs of lameness. The same study reported a decrease in body condition score for cows treated with rBST, though an increase in their dry matter intake occurred. Another meta-analysis (2003) reported on body condition scores (BCS) but could not reach a conclusion due to lack of homogeneity in study design and reporting. They found a trend towards decreased BCS in treated cows but state "Depending on the level of body condition in these cows, this effect may have been beneficial or detrimental." This analysis did not report on clinical mastitis. A more recent meta-analysis (2014) published by the Journal of the American Veterinary Medical Association showed no significant increase in risk of clinical mastitis nor other adverse effects on cow health and well-being. This review included 26 peer-reviewed studies that involved the use of the rBST-Zn formulation available to US producers in accordance with the label instructions for treatment initiation (57 to 70 days after birth), dose (500 mg, every 14 days), and route (subcutaneous). Mastitis has cost American dairy industries an estimated $1.5 to 2 billion per year in treating dairy cows.
== Clinical relevance == Using MFAP4-deficient mouse models, studies have shown roles for MFAP4 in neointima formation and asthma. Moreover, it has recently been shown that the glycosylation of MFAP4 is raised in the aortic extracellular matrix of Marfan syndrome patients using proteomics and gene expression levels of MFAP4 correlate with alterations in extracellular matrix genes within human aortic vascular smooth muscle cells.
Sources: en.wikipedia.org
From the 1830s Haüy's molecular crystal structure theory started to be combined with the atomic theory of the chemists to produce a view of a crystal as the regular arrangement of atoms or molecules in space. In 1849 Auguste Bravais related the symmetry of the crystal, considered as one of 14 space lattices, to that of its constituting molecules and formalized the reticular interpretation of hemihedry given by Gabriel Delafosse. In 1852 Delafosse attempted to relate the structure of the molecule to the external shape of the crystal. During the 1850s and 1860s a "quiet revolution" took place in structural chemistry according to Alan J. Rocke, a historian of chemistry. The main features of the revolution were the clarification of the concept of atomic weight (Stanislao Cannizzaro), the definition of the idea of valence (then known as atomicity), and new chemical structural ideas, such as the benzene structure of a ring of alternating double and single carbon bonds (August Kekulé). These developments in chemistry were largely independent of the mathematical and geometrical direction of crystallography in the period 1850–1895 which had little concern with the practicalities of atomic and molecular arrangement. In 1869 Emanuele Paternò predicted that the four valences of carbon have identical chemical properties and illustrated three predicted isomers of dibromethane showing the tetrahedral carbon atom for the first time. While Paternò's work was the first publication of tetrahedral-valent carbon it is not clear that he recognized the full consequences of the hypothesis.
=== 13 February === Thomas Bach, head of the IOC, stood by the offer of allowing Russian and Belarusian athletes to participate under a white or neutral flag for the 2024 Paris Olympics, saying that national governments should not decide who can participate in sports competitions. It was reported that Pakistan had sent some 10,000 Grad rockets to Ukraine in February.
== Licenses and collaborations == In January 2008, Rosetta Genomics announced a collaboration agreement with the Henry Ford Health System in Detroit, Michigan to develop microRNA-based diagnostics and prognostics for brain cancer. Also in January 2008, Rosetta Genomics announced that its subsidiary, Rosetta Genomics Inc. has received a license to use Roche Molecular Systems' PCR technology in microRNA-based diagnostic tests. In September 2007, Rosetta Genomics said it will work with New York University Medical Center to develop a microRNA-based diagnostic test for melanoma. In May 2007, Rosetta Genomics announced Columbia University Medical Center would utilize its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory to perform the clinical validation of Rosetta Genomics’ diagnostics program for cancer of unknown primary. In February 2006, Isis Pharmaceuticals Inc. and Rosetta Genomics said they will collaborate to develop antisense drugs that inhibit microRNA in the liver to treat cancers there. Antisense drugs are a class of compounds that interfere with genetic material that gets translated into harmful proteins.
Because the plant has not been well-studied in high-quality clinical research, little is known about its toxicology, adverse effects, or safety over long-term consumption. Its chief active psychoactive constituent is a structurally unique diterpenoid called salvinorin A, a potent κ-opioid agonist. Although not thoroughly assessed, preliminary research indicates S. divinorum may have low toxicity (high LD50). Its effects are rapid but short-lived.
Sources: en.wikipedia.org
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.
Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.
No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.